Back to home
INCY logo

Is INCY (Incyte Corporation) Halal or Haram?

NASDAQ Global SelectHealthcareBiotechnology$19.45B2026-04-29
INCY is Halal4/4 screens passed

Incyte Corporation successfully passes all AAOIFI shariah screens, making it a compliant investment for Muslim investors. The company maintains an exceptionally low debt-to-market cap ratio of just 0.4%, well below the 33% threshold. Additionally, its interest income stands at a permissible 2.05% of revenue, comfortably under the 5% limit.

Price Chart (5D)

$96.89+2.31 (+2.44%)
2026-05-012026-04-24

INCY — Last 7 Days

DateOpenHighLowCloseVolumeChange
2026-05-0195.2697.0594.8296.911.2M+1.73%
2026-04-30100.33100.8594.9395.272.4M-5.04%
2026-04-2999.18102.8696.6799.102.2M-0.08%
2026-04-2894.7598.3692.7997.742.5M+3.16%
2026-04-2794.5097.6694.5095.722.1M+1.29%
2026-04-2494.9595.2093.6394.651.1M-0.32%
2026-04-2396.3797.2595.1095.47905K-0.93%

Discussion

Sign in to join the discussion

Loading comments...

Shariah Screening Details for INCY

Business Activity

Permissible

Incyte Corporation's business passes the screening as its core focus on developing and commercializing biopharmaceutical therapeutics like JAKAFI and PEMAZYRE for oncology and blood disorders is universally permissible.

Debt / Market Cap

0.36%

Debt: $69.4MThreshold: ≤33%

Interest Income

2.05%

Interest: $105.6MThreshold: ≤5%

Cash & Securities

18.41%

Cash: $3.58BThreshold: ≤33%

About Incyte Corporation (INCY)

Incyte Corporation is a leading biopharmaceutical company focused on discovering and commercializing proprietary therapeutics for oncology and blood disorders. Its core portfolio includes widely used drugs like JAKAFI for myelofibrosis, PEMAZYRE for certain tumor types, and ICLUSIG for chronic myeloid leukemia.

For Muslim investors, Incyte represents a solid Halal investment opportunity within the biotechnology sector. The stock successfully passes all four AAOIFI screening criteria, meaning its core business operations and financial structures align perfectly with Islamic finance principles.

From a financial perspective, the company boasts an incredibly clean balance sheet, highlighted by a negligible debt-to-market cap ratio of just 0.4%. Furthermore, its cash and interest-bearing securities account for 18.4% of its market cap, and interest income remains well within the permissible limit at 2.05% of total revenue.

Since the core business of developing life-saving therapeutics is universally accepted as permissible, there is no significant scholarly debate regarding its operations. However, halal investors should periodically monitor its cash reserves and interest income to ensure they do not creep above the 5% revenue threshold during high-interest rate environments.

CEO

William J. Meury

Employees

2,617

IPO Date

1993-11-04

Headquarters

Wilmington, DE, US

INCY Key Financial Statistics

Revenue

$5.14B

Net Income

$1.29B

EPS (Diluted)

$6.41

Stock Price

97.74

Beta

0.86

52-Week Range

57.77-112.29

Total Debt

$69.4M

Total Equity

$5.17B

Current Ratio

3.32

INCY Financial Health & Profitability

Profit Margins

Gross Margin91.5%
Operating Margin26.1%
Net Margin25.0%

Revenue Growth (YoY)

+21.2%

Prior year: $4.24B

Net Cash

$3.03B

Cash: $3.10B — Debt: $69.4M

R&D Spending

$1.98B

% of Revenue

38.6%

Frequently Asked Questions About INCY

Is INCY (Incyte Corporation) stock halal to invest in?
Based on our AAOIFI-standard shariah screening, INCY is Halal and considered permissible for Muslim investors. It passed all 4 of 4 compliance screens including business activity review, debt-to-market-cap ratio (0.36% vs ≤33% threshold), interest income ratio (2.05% vs ≤5% threshold), and cash & securities ratio (18.41% vs ≤33% threshold).
What does Incyte Corporation do?
Incyte Corporation is a leading biopharmaceutical company focused on discovering and commercializing proprietary therapeutics for oncology and blood disorders. Its core portfolio includes widely used drugs like JAKAFI for myelofibrosis, PEMAZYRE for certain tumor types, and ICLUSIG for chronic myeloid leukemia. For Muslim investors, Incyte represents a solid Halal investment opportunity within the biotechnology sector. The stock successfully passes all four AAOIFI screening criteria, meaning its core business operations and financial structures align perfectly with Islamic finance principles. From a financial perspective, the company boasts an incredibly clean balance sheet, highlighted by a negligible debt-to-market cap ratio of just 0.4%. Furthermore, its cash and interest-bearing securities account for 18.4% of its market cap, and interest income remains well within the permissible limit at 2.05% of total revenue. Since the core business of developing life-saving therapeutics is universally accepted as permissible, there is no significant scholarly debate regarding its operations. However, halal investors should periodically monitor its cash reserves and interest income to ensure they do not creep above the 5% revenue threshold during high-interest rate environments. Incyte Corporation operates in the Healthcare sector under the Biotechnology industry and is headquartered in Wilmington, DE, US. The company is led by CEO William J. Meury and employs approximately 2,617 people.
What screening criteria were used for INCY?
INCY was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. INCY passed 4 of these 4 screens.
Does INCY require income purification?
Although INCY passes all shariah screens, it does earn $105.6M in interest income (2.05% of revenue). Many scholars recommend purifying this portion by donating the equivalent percentage of any dividends received to charity. For example, if you receive $100 in dividends, you would donate approximately $2.05 to purify the income.
When was INCY last screened?
INCY was last screened on 2026-04-29. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.

Disclaimer

This shariah compliance assessment for INCY (Incyte Corporation) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.

Other Halal Stocks in Healthcare